Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Ovarian Neoplasms

  Free Subscription

Articles published in Cancer Chemother Pharmacol

Retrieve available abstracts of 15 articles:
HTML format

Single Articles

    October 2021
  1. ROY P, Biswas S, Acharyya S, Dasgupta C, et al
    Effect of carboplatin dose capping on survival in recurrent breast, ovary and head and neck cancers: a single institutional retrospective study.
    Cancer Chemother Pharmacol. 2021;88:731-740.
    PubMed     Abstract available

    July 2021
  2. SUGISAWA N, Higuchi T, Han Q, Hozumi C, et al
    Oral recombinant methioninase combined with paclitaxel arrests recalcitrant ovarian clear cell carcinoma growth in a patient-derived orthotopic xenograft (PDOX) nude-mouse model.
    Cancer Chemother Pharmacol. 2021;88:61-67.
    PubMed     Abstract available

    June 2021
  3. SOKOLENKO AP, Gorodnova TV, Bizin IV, Kuligina ES, et al
    Molecular predictors of the outcome of paclitaxel plus carboplatin neoadjuvant therapy in high-grade serous ovarian cancer patients.
    Cancer Chemother Pharmacol. 2021 Jun 2. pii: 10.1007/s00280-021-04301.
    PubMed     Abstract available

    April 2021
  4. VAULEON E, Behal H, Lebellec L, Desbarbieux R, et al
    Does bevacizumab increase joint pain in patients with cancer? Results of the prospective observational BEVARTHRALGIA study.
    Cancer Chemother Pharmacol. 2021;87:533-541.
    PubMed     Abstract available

    January 2021
  5. LIU YK, Jia YJ, Liu SH, Ma J, et al
    FSTL1 increases cisplatin sensitivity in epithelial ovarian cancer cells by inhibition of NF-kappaB pathway.
    Cancer Chemother Pharmacol. 2021 Jan 3. pii: 10.1007/s00280-020-04215.
    PubMed     Abstract available

    October 2020
  6. HANSEN MKG, Smerdel MP, Waldstrom M, Andersen RF, et al
    Carboplatin re-treatment in platinum-resistant epithelial ovarian cancer patients.
    Cancer Chemother Pharmacol. 2020 Oct 16. pii: 10.1007/s00280-020-04162.
    PubMed     Abstract available

    August 2020
  7. JIANG J, Wang S, Wang Z, Cai J, et al
    HOTAIR promotes paclitaxel resistance by regulating CHEK1 in ovarian cancer.
    Cancer Chemother Pharmacol. 2020 Aug 2. pii: 10.1007/s00280-020-04120.
    PubMed     Abstract available

    June 2020
  8. ZHU Y, Liu Z, Qu Y, Zeng J, et al
    YLZ-F5, a novel polo-like kinase 4 inhibitor, inhibits human ovarian cancer cell growth by inducing apoptosis and mitotic defects.
    Cancer Chemother Pharmacol. 2020 Jun 9. pii: 10.1007/s00280-020-04098.
    PubMed     Abstract available

    April 2020
  9. SOYAMA H, Miyamoto M, Matsuura H, Iwahashi H, et al
    Rapid decrease in serum VEGF-A levels may be a worse prognostic biomarker for patients with platinum-resistant recurrent ovarian cancer treated with bevacizumab and gemcitabine.
    Cancer Chemother Pharmacol. 2020 Apr 11. pii: 10.1007/s00280-020-04070.
    PubMed     Abstract available

    January 2020
  10. WANG Z, Gao J, Ohno Y, Liu H, et al
    Rosiglitazone ameliorates senescence and promotes apoptosis in ovarian cancer induced by olaparib.
    Cancer Chemother Pharmacol. 2020 Jan 6. pii: 10.1007/s00280-019-04025.
    PubMed     Abstract available

    November 2019
  11. KASHANI B, Zandi Z, Bashash D, Zaghal A, et al
    Small molecule inhibitor of TLR4 inhibits ovarian cancer cell proliferation: new insight into the anticancer effect of TAK-242 (Resatorvid).
    Cancer Chemother Pharmacol. 2019 Nov 30. pii: 10.1007/s00280-019-03988.
    PubMed     Abstract available

  12. KUBECEK O, Martinkova J, Chladek J, Blaha M, et al
    Plasmafiltration as an effective method in the removal of circulating pegylated liposomal doxorubicin (PLD) and the reduction of mucocutaneous toxicity during the treatment of advanced platinum-resistant ovarian cancer.
    Cancer Chemother Pharmacol. 2019 Nov 14. pii: 10.1007/s00280-019-03976.
    PubMed     Abstract available

    October 2019
  13. ZHENG Y, Zhu J, Zhang H, Liu Y, et al
    Metformin plus first-line chemotherapy versus chemotherapy alone in the treatment of epithelial ovarian cancer: a prospective open-label pilot trial.
    Cancer Chemother Pharmacol. 2019 Oct 18. pii: 10.1007/s00280-019-03963.
    PubMed     Abstract available

    April 2019
  14. MOORE K, Chan JK, Secord AA, Patel MR, et al
    Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.
    Cancer Chemother Pharmacol. 2019;83:717-726.
    PubMed     Abstract available

    January 2019
  15. STARLING BR, Kumar P, Lucas AT, Barrow D, et al
    Mononuclear phagocyte system function and nanoparticle pharmacology in obese and normal weight ovarian and endometrial cancer patients.
    Cancer Chemother Pharmacol. 2019;83:61-70.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.